SG&A Expense Trends: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This article delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Wave Life Sciences Ltd. and Evotec SE, from 2014 to 2023.

A Decade of Growth

Over the past decade, Evotec SE has seen a staggering 843% increase in SG&A expenses, reflecting its aggressive expansion and strategic investments. In contrast, Wave Life Sciences Ltd. experienced a more modest growth of 1,610%, indicating a steady yet cautious approach to scaling operations.

Year-on-Year Insights

By 2023, Evotec SE's SG&A expenses reached approximately 170 million, a testament to its robust growth strategy. Meanwhile, Wave Life Sciences Ltd. reported expenses of around 51 million, showcasing its commitment to sustainable development.

These trends highlight the diverse strategies employed by biotech companies in navigating the competitive landscape.